Chart of the Week: The “exponential” second wave of COVID-19 in France explained

Macro

Christopher Dembik

Head of Macro Analysis

Summary:  Our 'Macro Chartmania' series collects Macrobond data and focuses on a single chart chosen for its relevance.


Click here to download this week's full edition of Macro Chartmania.

In today’s edition, we have done some data crunching about COVID-19 numbers in France in order to better understand the risk of second wave and its potential impact on the economy. France is one of the European countries that has been in the spotlight recently due to the strong increase in new COVID-19 cases. In the space of one week, the official daily count of new cases has almost doubled to reach 5,413 and the daily number of new identified clusters has also almost doubled to 40 (as of yesterday). The sharp increase is also confirmed if we look at the 7-day moving average. The number of new cases is at 4,932 versus 3,211 one week ago. Health authorities are now talking about “exponential” second wave of the virus and new social distancing measures have been implemented, such as mandatory mask-wearing in all public spaces (indoors and outdoors) in the biggest cities and compulsory mask-wearing in workplace everywhere in France, as of Sept. 1 (with some exceptions to the rule).

However, contrary to the situation that prevailed in late March/April, the number of fatalities is almost close to zero (13 fatalities as of August 29 vs around 1,000 at the height of the crisis) and new hospital and intensive care unit (ICU) entries are still very limited. At the height of the crisis, the number of patients in intensive care was above 7,000 versus less than 400 nowadays. To some extent, the situation is a little incongruous: we are in the midst of a massive pandemic but hospitals are basically empty. Let’s dig into data. The surge in new cases, which is considered as “exponential”, is certainly partially the result of increased testing. On a weekly basis, the government is currently running about 800,000 tests and wants to reach the threshold of 1,000,000 per week shortly. Another explanation is that young adults, which represent a growing number of new cases but are more resilient than older people, are less vigilant and more reluctant to strictly respect social distancing measures, thus facilitating the spread of the virus. Despite the surge in the number of new cases, the pandemic seems to be under control for the moment. However, we are not out of the woods yet. It is unclear whether the health system will have the capacity to simultaneously deal with COVID-19 and flu this fall if the number of hospital and intensive care unit entries would sharply rise.

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

Saxo Capital Markets HK is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo Capital Markets HK Limited holds a Type 1 Regulated Activity (Dealing in securities); Type 2 Regulated Activity (Dealing in Futures Contract) and Type 3 Regulated Activity (Leveraged foreign exchange trading) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong

By clicking on certain links on this site, you are aware and agree to leave the website of Saxo Capital Markets, proceed on to the linked site managed by Saxo Group and where you will be subject to the terms of that linked site.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

Please note that the information on this site and any product and services we offer are not targeted at investors residing in the United States and Japan, and are not intended for distribution to, or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Please click here to view our full disclaimer.